OncoZenge AB (OSTO:ONCOZ) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ONCOZ OncoZenge AB OSTO:ONCOZ
26 GF Score
Price kr7.49
! 2 Warning Signs
View Full Analysis

What is OncoZenge AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:ONCOZ
26GF Score
OncoZenge AB OSTO:ONCOZ
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoZenge AB Business Description

Address Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score

Get the complete analysis for OSTO:ONCOZ

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.49
Price